A subcutaneous injection of the immune-boosting drug teclistamab was found to be safe and elicit responses in a majority of patients with relapsed or refractory multiple myeloma, according to findings from a multi-institutional ...
Dec 6, 2020
0
7
AL amyloidosis is a life-threatening disease related to bone marrow cancer and multiple myeloma. It is caused when a person's antibody-producing white blood cells (i.e. plasma cells) do not function properly and generate ...
Jul 14, 2022
0
3
Metastatic breast cancer can be a daunting diagnosis, but the prognosis has improved somewhat with advances in treatment.
Jun 26, 2023
0
9
Eligibility requirements for clinical trials help protect patients whose comorbidities may put them at an additional risk of severe harm from the treatment being tested. Further, they help ensure that analyses are performed ...
Jun 27, 2024
0
0
(HealthDay)—For patients with advanced endometrial cancer, lenvatinib plus pembrolizumab results in significantly longer progression-free and overall survival than the physician's choice of chemotherapy, according to a ...
Jan 31, 2022
0
3
The U.S. Food and Drug Administration approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for treatment of adults with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer ...
Apr 14, 2022
0
2
Immune checkpoint inhibitors (ICIs) are used to treat a variety of different cancers. ICIs are antibodies that sensitize the body's own immune system to detect and destroy tumors. However, ICIs are not effective in all patients, ...
Jan 3, 2024
0
50
An immunotherapy drug called 'avelumab' has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Professor Tom Powles ...
May 29, 2020
0
3
Adding ipilimumab to pembrolizumab does not improve efficacy and is associated with greater toxicity than pembrolizumab alone as first-line therapy for metastatic non-small cell lung cancer (NSCLC) for patients with a PD-L1 ...
Jan 30, 2021
0
3
For patients with immunoglobulin D multiple myeloma (IgD MM), those with renal impairment (RI) have poorer prognosis and shorter median survival than those with no renal impairment (no-RI), according to a study published ...
Dec 20, 2022
0
2
